Published on 18 Mar 2024 on Zacks via Yahoo Finance
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
Immuneering Corporation IMRX is a clinical-stage biotech company focused on developing universal-RAS/RAF medicines to treat cancer patients.
Devoid of marketed drugs in its portfolio, Immuneering is entirely dependent on its pipeline for growth. The company’s lead pipeline candidate is IMM-1-104, an investigational RAS medication, which is being evaluated in a phase I/IIa study in patients with advanced solid tumors harboring RAS mutations.
In the past week, Immuneering’s shares have plunged 70.9% compared with the industry’s 2.1% fall. This downside came after the company reported topline results from the phase I portion of the phase I/IIa study on IMM-1-104 last week.